Gene Therapy Research Reports, May 2013

You might be interested in: therapeutics, cancer, medical equipment, more »


 

1-10 of 31 reports for Gene Therapy
US Stem Cell Market Analysis

US Stem Cell Market Analysis

  • $ 800
  • Industry report
  • April 2011
  • by RNCOS

The stem cell market has been growing at a fast pace for the past few years and despite recession, the US continued to witness positive developments and massive investments in this industry. Using stem ...

Oxford BioMedica plc (Symbol:OXB) SWOT Analysis, Strategy, Revenues and Profits

Oxford BioMedica plc (Symbol:OXB) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • May 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Antisense Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Antisense Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • April 2013
  • by Global Data

Summary Antisense Pharma GmBH (Antisense) is a biotechnology company. The company develops and markets antisense technology based drugs for the treatment of cancer and other incurable diseases. It provides ...

Cell Medica Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cell Medica Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • April 2013
  • by Global Data

Summary Cell Medica Limited (Cell Medica) is a healthcare company, based in the UK. It is in the development of cell therapies for the treatment of various diseases. The company is a partnership of scientists, ...

Gene Therapy in Oncology Drug Pipeline Update 2013

Gene Therapy in Oncology Drug Pipeline Update 2013

  • $ 2 249
  • Industry report
  • April 2013
  • by Bioseeker

There are today 120 companies plus partners developing 109 gene therapy drugs in 257 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs ...

Isis Pharmaceuticals, Inc. (Symbol:ISIS) SWOT Analysis, Strategy, Revenues and Profits

Isis Pharmaceuticals, Inc. (Symbol:ISIS) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • April 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

ReGenX Biosciences, LLC SWOT Analysis, Strategy, Revenues and Profits

ReGenX Biosciences, LLC SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • March 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Antisense Therapeutics Limited (Symbol:ANP) SWOT Analysis, Strategy, Revenues and Profits

Antisense Therapeutics Limited (Symbol:ANP) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • March 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

uniQure BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

uniQure BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • February 2013
  • by Global Data

Summary uniQure BV (uniQure) develops human gene based therapies. The company's technologies and capacities include platform vector technology, platform manufacturing technology, clinical development and ...

ReGenX Biosciences, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ReGenX Biosciences, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2013
  • by Global Data

Summary ReGenX Biosciences, LLC (ReGenX) is a bio pharmaceutical company that is engaged in research and development of therapeutics based on adeno-associated viral vectors (AAV vectors). These vectors ...


Privacy Policy by TRUSTe
ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.